Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXQ-350 in Pediatric Relapsed Solid Tumors
NCT03967093Phase 1Terminated
- Sponsor
- Bexion Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of BXQ-350 in solid tumor, brain cancer, ependymoma and 1 more (5 arms), sponsored by Bexion Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 6 months, Maximum Tolerated Dose at 6 months and 3 more. Started Apr 2019; status: terminated.
02
Drugs
BXQ-350
03
Conditions
solid tumorbrain cancerependymomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03967093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967093.